Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL

Leukemia and Lymphoma

Volumn 52, Issue SUPPL. 1, 2011, Pages 45-53

  Redig, Amanda J ^a,b   Vakana, Eliza ^a   Platanias, Leonidas C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

BCR ABL; CML; mTOR

Indexed keywords

BCR ABL PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DOWN REGULATION; DRUG DESIGN; ENZYME PHOSPHORYLATION; LEUKEMIA; LEUKEMOGENESIS; NONHUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 79951487809     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.546919     Document Type: Review

References (98)

1. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112:4808-4817.
2. Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. J Clin Invest 2007;117: 2067-2074. (Pubitemid 47219546)
3. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25: 85-109.
4. Stock W. Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leuke-mia. Leuk Lymphoma 2010;51:188-198.
5. Soupir CP, Vergilio JA, Dal Cin P, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggres-sive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol 2007;127:642-650. (Pubitemid 46587480)
6. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003;101:4667-4679. (Pubitemid 36857719)
7. Morrison DK, Davis RJ. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol 2003;19:91-118. (Pubitemid 37487344)
8. Strniskova M, Barancik M, Ravingerova T. Mitogen-activated protein kinases and their role in regulation of cellular processes. Gen Physiol Biophys 2002;21:231-255. (Pubitemid 35282663)
9. Rincón M, Flavell RA, Davis RJ. Signal transduction by MAP kinases in T lymphocytes. Oncogene 2001;20:2490-2497. (Pubitemid 32531305)
10. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 2002;20:55-72. (Pubitemid 34293420)
11. Rincón M, Davis RJ. Regulation of the immune response by stress-activated protein kinases. Immunol Rev 2009;228:212-224.
12. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-3356.
13. Chen KC, Liu WH, Chang LS. Suppression of ERK signaling evokes autocrine Fas-mediated death in arachidonic acid-treated human chronic myeloid leukemia K562 cells. J Cell Physiol 2010;222:625-634.
14. Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, et al. ERK2, but not ERK1, mediates acquired and 'de novo' resistance to imatinib mesylate: implication for CML therapy. PLoS One 2009;4:e6124.
15. Coppo P, Dusanter-Fourt I, Vainchenker W, Turhan AG. BCR-ABL induces opposite phenotypes in murine ES cells according to STAT3 activation levels. Cell Signal 2009;21: 52-60.
16. McCubrey JA, Steelman LS, Abrams SL, et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008;22:708-722. (Pubitemid 351565619)
17. Liu XY, Yang YF, Wu CT, et al. Spred2 is involved in imatinib-induced cytotoxicity in chronic myeloid leukemia cells. Biochem Biophys Res Commun 2010;393:637-642.
18. McCallum L, Lu W, Price S, Lazar N, Perbal B, Irvine AE. CCN3: a key growth regulator in chronic myeloid leukaemia. J Cell Commun Signal 2009;3:115-124.
19. Jin A, Kurosu T, Tsuji K, et al. BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhe-sion. Oncogene 2006; 25:4332-4340. (Pubitemid 44100503)
20. Mizuchi D, Kurosu T, Kida A, et al. BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells. Biochem Biophys Res Commun 2005;326:645-651. (Pubitemid 39642773)
21. Yasuda T, Shirakata M, Iwama A, et al. Role ofDok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia. J Exp Med 2004;200:1681-1687. (Pubitemid 40103560)
22. Coppo P, Flamant S, De Mas V, et al. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 2006;134:171-179. (Pubitemid 43893908)
23. Nakamura Y, Yujiri T, Nawata R, Tagami K, Tanizawa Y. MEK kinase 1 is essential for Bcr-Abl-induced STAT3 and self-renewal activity in embryonic stem cells. Oncogene 2005; 24:7592-7598. (Pubitemid 41638033)
24. Notari M, Neviani P, Santhanam R, et al. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood 2006;107:2507-2516. (Pubitemid 43345575)
25. Aichberger KJ, Mayerhofer M, Krauth MT, et al. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCRABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic com-pounds. Cancer Res 2005;65:9436-9444. (Pubitemid 41508012)
26. Aichberger KJ, Mayerhofer M, Krauth MT, et al. Identifica-tion of mcl-1 as a BCRABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileu-kemic effects ofimatinib and mcl-1 antisense oligonucleotides. Blood 2005;105:3303-3311.
27. Nguyen TK, Rahmani M, Harada H, Dent P, Grant S. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood 2007;109: 4006-4015. (Pubitemid 46641754)
28. Suzuki M, Abe A, Imagama S, et al. BCR-ABL-independent and RAS/MAPK pathway-dependent form of imatinib resis-tance in Ph-positive acute lymphoblastic leukemia cell line with activation ofEphB4. Eur J Haematol 2010;84:229-238.
29. Bonhoure E, Lauret A, Barnes DJ, et al. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia 2008;22: 971-979. (Pubitemid 351689879)
30. Zhang M, Fu W, Prabhu S, et al. Inhibition of polysome assembly enhances imatinib activity against chronic myelo-genous leukemia and overcomes imatinib resistance. Mol Cell Biol 2008;28:6496-6509.
31. Jorgensen HG, Holyoake TL. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans 2007;35:1347-1351. (Pubitemid 350206497)
32. Nguyen TK, Rahmani M, Gao N, et al. Synergistic interac-tions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. Clin Cancer Res 2006;12: 2239-2247.
33. Yu C, Dasmahapatra G, Dent P, Grant S. Synergistic interactions between MEK1/2 and histone deacetylase in-hibitors in BCR/ABL+ human leukemia cells. Leukemia 2005;19:1579-1589. (Pubitemid 43090402)
34. Yu C, Subler M, Rahmani M, et al. Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. Cancer Biol Ther 2003;2:544-551.
35. Sanchez-Arevalo Lobo VJ, Aceves Luquero CI, Alvarez-Vallina L, et al. Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implica-tions in the cellular response to Ara-C. Biochem J 2005;387: 231-238. (Pubitemid 40524093)
36. Bandyopadhyay G, Biswas T, Roy KC, et al. Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells. Blood 2004;104:2514-2522. (Pubitemid 39331855)
37. Mayer IA, Verma A, Grumbach IM, et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem 2001;276: 28570-28577.
38. Wong S, McLaughlin J, Cheng D, Witte ON. Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. Blood 2003;101:4088-4097. (Pubitemid 36857890)
39. Korus M, Mahon GM, Cheng L, Whitehead IP. p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr. Oncogene 2002;21:4601-4612. (Pubitemid 34833138)
40. Iotti G, Ferrari-Amorotti G, Rosafio C, et al. Expression of CCL9/MIP-1gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABLcells. Oncogene 2007;26:3482-3491. (Pubitemid 46816764)
41. Katsoulidis E, Sassano A, Majchrzak-Kita B, et al. Suppres-sion of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells. J Biol Chem 2008;283:10793-10803.
42. Parmar S, Katsoulidis E, Verma A, et al. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem 2004;279:25345-25352. (Pubitemid 38756790)
43. Dumka D, Puri P, Carayol N, et al. Activation ofthe p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma 2009;50:2017-2029.
44. Maia V, Sanz M, Gutierrez-Berzal J, et al. C3G silencing enhances STI-571-induced apoptosis in CML cells through p38 MAPK activation, but it antagonizes STI-571 inhibitory effect on survival. Cell Signal 2009;21:1229-1235.
45. Galan-Moya EM, Hernandez-Losa J, Aceves Luquero CI, et al. c-Abl activates p38 MAPK independently of its tyrosine kinase activity: implications in cisplatin-based therapy. Int J Cancer 2008;122:289-297. (Pubitemid 350234714)
46. Carter TA, Wodicka LM, Shah NP, et al. Inhibition ofdrug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005;102:11011-11016. (Pubitemid 41105984)
47. Jacquel A, Colosetti P, Grosso S, et al. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition. Oncogene 2007;26: 2445-2458. (Pubitemid 46597264)
48. Merkerova M, Klamova H, Brdicka R, Bruchova H. Targeting ofgene expression by siRNA in CML primary cells. Mol Biol Rep 2007;34:27-33. (Pubitemid 46220354)
49. Mancini M, Veljkovic N, Corradi V, et al. 14-3-3 Ligand prevents nuclear import of c-ABL protein in chronic myeloid leukemia. Traffic 2009;10:637-647.
50. Hess P, Pihan G, Sawyers CL, Flavell RA, Davis RJ. Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet 2002;32:201-205. (Pubitemid 34977219)
51. Hoornaert I, Marynen P, Goris J, Sciot R, Baens M. MAPK phosphatase DUSP16/MKP-7, a candidate tumor suppressor for chromosome region 12p12-13, reduces BCR-ABL-in-duced transformation. Oncogene 2003;22:7728-7736. (Pubitemid 37485532)
52. Puissant A, Robert G, Fenouille N, et al. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 2010;70:1042-1052.
53. Nica AF, Tsao CC, Watt JC, et al. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK Cell Cycle 2008;7:3362-3370.
54. Mao X, Yu CR, Li WH, Li WX. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell Res 2008;18:879-888.
55. Potin S, Bertoglio J, Bréard J. Involvement of a Rho-ROCK-JNK pathway in arsenic trioxide-induced apoptosis in chronic myelogenous leukemia cells. FEBS Lett 2007;581:118-124. (Pubitemid 44960294)
56. Gingras AC, Raught B, Sonenberg N. Regulation of transla-tion initiation by FRAP/mTOR. Genes Dev 2001;15:807-826.
57. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-1945. (Pubitemid 39071573)
58. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-183. (Pubitemid 41317589)
59. Platanias LC. Mechanisms of type I and II interferon signaling. Nat Rev Immunol 2005;5: 375-386.
60. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4: 335-348.
61. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordi-nator of cell growth and cell cycle progression. Oncogene 2004;23:3151-3171. (Pubitemid 38638827)
62. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22. (Pubitemid 47001784)
63. Altman JK, Platanias LC. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Curr Opin Hematol 2008;15:88-94. (Pubitemid 351323147)
64. Kroczynska B, Kaur S, Platanias LC. Growth suppressive cytokines and the AKT/mTOR pathway. Cytokine 2009;48: 138-143.
65. Ma XM, Blenis J. Molecular mechanisms of mTOR mediated translational control. Nat Rev Mol Cell Biol 2009;10:307-318.
66. Peng T, Golub TR, Sabatini DM. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol 2002;22:5575-5584. (Pubitemid 34755766)
67. Martelli AM, Nyakern M, Tabellini G, et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implica-tions for human acute myeloid leukemia. Leukemia 2006;20: 911-928. (Pubitemid 43797279)
68. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA. Targeting the PI3'K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 2009;18:1333-1349.
69. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007;12:487-502. (Pubitemid 46523652)
70. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002;110:163-175. (Pubitemid 34876545)
71. Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 2010;33: 67-75.
72. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol 2005;15: 702-713. (Pubitemid 40599924)
73. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner ofmTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296-1302. (Pubitemid 38991819)
74. Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002;100:3767-3775. (Pubitemid 35303950)
75. Mayerhofer M, Aichberger KJ, Florian S, et al. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppres-sive effects of rapamycin in leukemic cells. FASEB J 2005;19: 960-962. (Pubitemid 40827717)
76. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target ofrapamycin. Cancer Res 2003;63:5716-5722. (Pubitemid 37187466)
77. Mohi MG, Boulton C, Gu TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004;101:3130-3135. (Pubitemid 38327746)
78. Parmar S, Smith J, Sassano A, et al. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood 2005;106:2436-2443. (Pubitemid 41510818)
79. Markova B, Albers C, Breitenbuecher F, et al. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation ofmTOR/p70S6-kinase path-way. Oncogene 2010;29:739-751.
80. Kim JH, Chu SC, Gramlich JL, et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005;105: 1717-1723. (Pubitemid 40223695)
81. Carayol N, Katsoulidis E, Sassano A, Altman JK, Druker BJ, Platanias LC. Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engage-ment of the mTOR/p70 S6 kinase pathway. J Biol Chem 2008;283:8601-8610.
82. Cmarik JL, Min H, Hegamyer G, et al. Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA 1999;96: 14037-14042.
83. Yang HS, Knies JL, Stark C, Colburn N. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactiva-tion. Oncogene 2003;22:3712-3720. (Pubitemid 36760733)
84. Yang HS, Jansen AP, Komar AA, et al. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 2003;23:26-37. (Pubitemid 36008498)
85. Yang HS, Cho MH, Zakowicz H, Hegamyer G, Sonenberg N, Colburn NH. A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A. Mol Cell Biol 2004;24:3894-3906. (Pubitemid 38496167)
86. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. S6K1-and betaTRCP-mediated degradation ofPDCD4 promotes protein translation and cell growth. Science 2006;314:467-471. (Pubitemid 44628968)
87. Sonenberg N, Pause A. Signal transduction. Protein synthesis and oncogenesis meet again. Science 2006;314: 428-429. (Pubitemid 44628952)
88. Burchert A, Wang Y, Cai D, et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance develop-ment. Leukemia 2005;19:1774-1782. (Pubitemid 41486155)
89. Sillaber C, Mayerhofer M, Bohm A, et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest 2008;38:43-52. (Pubitemid 350293855)
90. Hirase C, Maeda Y, Takai S, Kanamaru A. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: possible clinical application of mTOR inhibitor. Leuk Res 2009;33: 450-459.
91. Mancini M, Corradi V, Petta S, Martinelli G, Barbieri E, Santucci MA. mTOR inhibitor RAD001 (everolimus) en-hances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. Leuk Res 2010;34:641-648.
92. Mancini M, Petta S, Martinelli G, Barbieri E, Santucci MA. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia. J Cell Biochem 2010;109:320-328.
93. Weisberg E, Banerji L, Wright RD, et al. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL-and mutant FLT3-expressing cells. Blood 2008;111:3723-3734.
94. Kharas MG, Janes MR, Scarfone VM, et al. Ablation ofPI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 2008;118:3038-3050.
95. Janes MR, Limon JJ, So L, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010;16:205-213.
96. Carayol N, Vakana E, Sassano A, et al. Critical roles for mTORC2 and rapamycin-insensitive mTORC1 complexes in growth and survival of BCR-ABL expressing cells. Proc Natl Acad Sci USA 2010;107:12469-12474.
97. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006;145: 913-923. (Pubitemid 351639967)
98. Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 2007;249:121-132. (Pubitemid 46452920)